Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE (DD-MM-YYYY)2. REPORT TYPE 3. DATES COVERED (From -To) 4. TITLE AND SUBTITLE 5a. CONTRACT NUMBER 5b. GRANT NUMBER 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) 5d. PROJECT NUMBER 5e. TASK NUMBER E-Mail:5f. WORK UNIT NUMBER Macrophages have been proposed as a potential target for manipulation of the microenvironment in breast cancer because they are potent effectors of the immune system. NF-kappaB (NF-κB) signaling in macrophages contributes to their impact during breast tumorigenesis. Thus, macrophage-targeted modulation of NF-κB has potential as a novel therapeutic approach for breast cancer. NF-κB signaling is mediated via two major pathways; the canonical/classical pathway and the alternative pathway. Our strategy is designed to develop a nanobiotechnology-based method to target siRNA designed to inhibit NF-κB classical and alternative signaling specifically to tumor associated macrophages to modulate the tumor microenvironment and to test the therapeutic potential of this approach. In this highly collaborative study, we have synthesized and characterized in vitro both mannosylated and untargeted nanoparticles. We have compared the efficiency of transfection of bone marrow derived macrophages between nanoparticles and commercial transfection reagents. We have started to investigate the effects of modulation of the NF-κB pathways on macrophage phenotype. Finally, we have performed initial in vivo studies that suggest that tumor associated macrophage specific targeting will be feasible in the context of primary tumors and metastases in the lung. Nanoparticles, NF-kappaB, macrophages, alternative NF-kappaB 301 fiona.yull@vanderbilt.edu Table of Contents Introduction…………………………………………………………………………… 1 Body…………………………………………………………………………………… 2
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTKey Research Accomplishments…………………………………………...